Glori Energy
Founded Year
2005Stage
Reverse Merger | IPOTotal Raised
$72.02MAbout Glori Energy
Glori Energy, formerly Glori Oil, works with oil producers to install the AERO System (Activated Environment for the Recovery of Oil) into existing production infrastructure to increase oil recovery. Glori's AERO System enhances production from waterflooded fields by stimulating a reservoir's naturally occurring microbes to improve water sweep and oil mobility. Waterflood technology injects water into reservoirs to release additional quantities of oil that were unrecoverable during primary recovery. Conventional waterflooding only extracts a fraction of all discovered oil, leaving the majority underground. Glori's AERO System provides a new, viable option to recover this trapped oil with minimal new footprint or investment.
Missing: Glori Energy's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Glori Energy's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Glori Energy Patents
Glori Energy has filed 10 patents.
The 3 most popular patent topics include:
- Light fixtures
- Mains power connectors
- Smart speakers
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/2/2019 | 7/7/2020 | Light fixtures, Mains power connectors, Wireless energy transfer, Smart speakers, Electrical engineering | Grant |
Application Date | 5/2/2019 |
|---|---|
Grant Date | 7/7/2020 |
Title | |
Related Topics | Light fixtures, Mains power connectors, Wireless energy transfer, Smart speakers, Electrical engineering |
Status | Grant |
Latest Glori Energy News
Jan 8, 2020
Round Led by New Investor Gentry Venture Partners January 24, 2012 09:00 AM Eastern Standard Time HOUSTON--( BUSINESS WIRE )--Glori Energy, a leader in sustainable, enhanced oil recovery and provider of the AEROTM (Activated Environment for Recovery of Oil) System, today announced the closing of a $20 million issue of its Series C Convertible Preferred Stock. Gentry Venture Partners, a Chicago-based venture firm that leads or co-invests with some of the world's premiere venture capital groups, led the $20 million investment. In addition to Gentry, new investor Advantage Capital Partners joined existing investors Energy Technology Ventures (a GE, NRG Energy and ConocoPhillips joint venture), GTI Ventures, Kleiner Perkins Caufield & Byers (KPCB), Oxford Bioscience Partners, Malaysian Life Sciences Capital Fund, and The Omzest Group in completing the funding round. Piper Jaffray acted as placement agent. Glori will use the proceeds to both expand its AEROTM technology service business and to acquire shut-in or low-producing mature fields for redevelopment utilizing its AEROTM System. Proven results in these shut-in fields will lead to increased product revenue, market value, and overall customer adoption of Glori’s System. “We are thrilled to have closed an important funding round with this exceptional group of investors,” said Stuart Page, CEO of Glori Energy. “Glori is looking forward to expanding our service business and acquiring new fields to deploy the AERO System.” “Glori has shown great promise in its previous field implementation projects,” said Larry Aschebrook, Managing Partner at Gentry Ventures Partners. “GVP is looking forward to seeing Glori expand its service business and acquire new fields to deploy its AERO System technology.” About Glori Energy Glori Energy’s mission is to sustainably and efficiently recover billions of barrels of oil trapped in reservoirs using existing oil wells. Glori partners with oil producers to significantly increase their oil production through the deployment of its AEROTM (Activated Environment for Recovery of Oil) System. The system makes use of existing non-potable water sources, optimizing the water quality to activate and sustain the indigenous reservoir microbial life with the desired metabolic activities. The AERO™ System provides a new, viable option to recover previously trapped oil with minimal new footprint or investment. For more information visit: www.GloriEnergy.com . About Gentry Ventures Partners Gentry Venture Partners is a specialized venture firm that leads or co-invests with some of the world's premiere venture capital groups in mid and late-stage financing for pre-IPO companies. GVP is active in a broad spectrum of investment sectors with a primary focus on biotech, cleantech, energy and information technology. Since its inception in 2006, Gentry Venture Distinguished by the extensive business experience of their partners, and their strong network of syndicate groups, Gentry Venture Partners provides broad services to its portfolio companies. For more information visit: www.GentryFinancialCorporation.com . Contacts
Glori Energy Frequently Asked Questions (FAQ)
When was Glori Energy founded?
Glori Energy was founded in 2005.
Where is Glori Energy's headquarters?
Glori Energy's headquarters is located at 4315 South Drive, Houston.
What is Glori Energy's latest funding round?
Glori Energy's latest funding round is Reverse Merger.
How much did Glori Energy raise?
Glori Energy raised a total of $72.02M.
Who are the investors of Glori Energy?
Investors of Glori Energy include Infinity Cross Border Acquisition Corp., GTI Capital Group, Oxford Bioscience Partners, Malaysian Life Sciences Capital Fund, Omzest and 8 more.
Who are Glori Energy's competitors?
Competitors of Glori Energy include Catalyst Biosciences, Pfenex, Bloomage BioTech, CMC Biologics, Ciris Energy and 16 more.
Compare Glori Energy to Competitors
The company provide business development services to clients in the pharmaceutical, biotechnology, consumer health, and drug delivery industries worldwide. The company's team members represent an array of nationalities and a mix of commercial, manufacturing, medical, and scientific expertise, gained from decades of experience with both global pharmaceutical and development-stage companies
AthenaES specializes in the development and commercialization of advanced biotechnology-based products. Throughout its eleven year history, the company has maintained a broad perspective for applying its core competency, the use of proteins and enzymes for commercial applications, to develop products. As such, the company currently markets its products and services through two business units and maintains an exploratory R&D group. The Athena Enzyme Systems Group aims to provide specialty reagents and proteins for the production and recovery of recombinant proteins along with providing contract R&D services. Products include: Expression Media, Serum-free Media, Protein Refolding kits, and the PDQ Protease Assay. This business unit also aims to provide specialized contract research, development and manufacturing services for the production of recombinant proteins. The Athena Environmental Services Group designs, develops and manufactures environmentally responsible products. Products developed include: The Bilge Pill, a biodegradable cleaning product for the removal of oil in boat bilges, and a plant nutrient supplement used in hydroponics, hobby gardens and horticulture that replaces conventional fertilizers, and the Sting Thing, an enzyme-based invertebrate sting treatment product. More recently, this group developed and has introduced a water-soluble, reversible glue, MagiGlue. The Athena Exploratory Science Group has the mission to pursue research with the potential for commercial, environmental and social impact. These projects are far reaching in their scope and represent high risk, high-value projects.
Laureate Pharma, Inc. is a full service contract manufacturing organization(CMO) providing development and cGMP manufacturing services in the company's FDA registered facilities in Princeton, New Jersey. The company is dedicated to supporting the development and commercialization of biopharmaceutical, drug and diagnostic products for pharmaceutical, diagnostic and biotech companies.The company aims to provide a range of product development and manufacturing services from cell line optimization and process design to development of full-scale cGMP protein production, purification and aseptic filling, in addition to corresponding testing, validation, analytical and regulatory support. The company's focus is on mammalian cell based monoclonal antibody and recombinant protein production for clinical and modest commercial supply.The company view the company's customers as partners and provide them with flexible solutions that reduce time to clinic and market. Focused on operational excellence, the company's highly experienced staff works with the company's customers to improve the quality of their products and processes.The company value the company's customers, stakeholders and associates. Therefore, the company measure the company's success by meeting the company's customers' needs, generating results in terms of quality, timeliness and on budget performance, as well as fostering an environment of trust, growth and diversity for the company's team.
SiTec Consulting was established in 1996, on the basis of long experience in pharmaceutical R&D. The company developed a range of expertise working with pharmaceutical and biotech companies in the United States and in Europe.n SiTec Consulting offers pharmaceutical and biotechnology companies a variety of services in the areas of preformulation, drug development, drug delivery and formulation technologies evaluation, regulatory and cGLP/cGMP compliance. The company can actively collaborate with start-up pharmaceutical and drug delivery companies to provide scientific and strategic support in the establishment of the new company's activities. The company emphasize open communication, active involvement with the client and continuous feedback.n Networking is one of the company's assets, allowing us to cover the complex demands of the R&D process. The company have access to laboratories and equipment and resources, located at the Bioindustry Park Canavese, and at selected universities and research centers in Europe. This aims to give the possibility to conduct and manage experimental parts of projects at the company's clients' request.n The company value the importance of high quality training. In addition to the hands-on experience the company can provide to the company's clients, SiTec is an authorized representative of the Center for Professional Advancement, a worldwide private institution dedicated to the provision of continuing technical and scientific education at a professional level.
Qyntessa Biologics aims to provide clinical manufacturing, (cGMP biologics manufacturing), process development, cell banking, cell line development, testing and fill/finish for researchers and biopharmaceutical companies who do not have the facilities and competencies for clinical manufacturing.
BioPro Pharmaceutical is the first regional biotech company in Asia to develop, market leading biopharmaceutical medicines, as well as many of the world's best known biopharmaceutical products. BioPro Pharmaceutical , Inc. has infrastructure in place in all major countries in Asia to target the market of US$30 billion. BioPro's expertise is in providing creative pharmaceutical solutions to small and medium-sized US or European companies by integrating Asia's respective business strengths in addressing the pharmaceutical needs of the Asia-Pacific region. We have the knowledge and know-how of the clinical and regulatory requirements across the Asian region . We manage more than 600 professional sales representatives. We are focused on the marketing and distribution of innovative biotech cancer products in Asian markets with the most cost-effective approaches. We anticipate intense competition in this new market sector, and are working diligently to stay at the forefront of this everchanging competitive environment. BioPro obtained the exclusive rights for the core patented technology - High Throughput Mammalian Protein Expression technology to develop cost effective protein products for bioassay and reagent support and " rapid mammalian production cell development technology and downstream support team for new generations of currently well-known and future protein drugs; We have three protein therapeutics, two antibody therapeutics and two vaccines under development.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.